A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorBristol-Myers Squibb
About this trial
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
Eligibility criteria
Qualifiers
None
Disqualifiers
Cohort A and B.
Other protocol-defined Inclusion/Exclusion criteria apply.
Trial design
Treatments tested in this trial
- BMS-986470
- Placebo
- Famotidine
Treatment groups
184 Participants
are divided into 5 treatment groupsLocations
34Canada
Local Institution - 0050V621Y6, VancouverBritish Columbia, Canada
Local Institution - 0051M5G 2C4, TorontoOntario, Canada
France
Institut de cancérologie Strasbourg Europe (ICANS)67033, StrasbourgAlsace, France
Local Institution - 006194000, Créteil France
Sponsors and collaborators
Bristol-Myers Squibb
Lead sponsor
Source ClinicalTrials.gov